Sign in
Active, not recruitingPhase 3

A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease

Key facts

Who runs it
Zenas BioPharma (USA), LLC
Where
Atlanta, Boston, Detroit, Naples, and Stanford, United StatesSee the 5 sitesAlso in 17 other countries, 71 sites
Trial code
Status
Active, not recruiting
Phase
Phase 3
People taking part
194 people enrolled
Started
9 Jan 2023
Expected to end
15 Feb 2029
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Obexelimab
  • Placebo
Record updated
4 February 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Males and females, ≥ 18 years of age
  • Clinical diagnosis of IgG4-RD
  • Patients must meet the 2019 ACR/EULAR Classification Criteria for IgG4-RD
  • Patients must have active IgG4-RD signs/symptoms (i.e., flare) that require the initiation of GC therapy or the increase in background long-term GC therapy
  • Other inclusion criteria apply

Who cannot take part

  • Has received prednisone equivalent given orally at a dose greater than 60 mg/day within the 4 weeks prior to screening or during screening
  • Has received a non-biologic, disease-modifying anti-rheumatological drug or immunosuppressive agent other than GCs within the 2 weeks prior to screening
  • Has received an investigational treatment or direct medical intervention on another clinical study within 12 weeks or < 5 half-lives of the investigational treatment, whichever is shorter, prior to screening
  • Has received live vaccine or live therapeutic infectious agent within the 2 weeks prior to screening
  • Has disease in only 1 organ system whose primary manifestation is fibrosis
  • Active tuberculosis or high risk for tuberculosis; hepatitis C infection in absence of curative treatment; evidence of hepatitis B infection
  • Use of B cell depleting or targeting agents within 6 months of randomization
  • Other exclusion criteria apply

Where in United States

Also in 17 other countries, 71 sites

  • Emory UniveristyAtlanta, United States
  • Massachusetts General HospitalBoston, United States
  • Henry Ford HospitalDetroit, United States
  • GI PROS Research - Dedicated Research FacilityNaples, United States
  • Stanford MedicineStanford, United States

About the trial

What the trial wants to find out

This study aims to examine the efficacy and safety of obexelimab for the prevention of flare of IgG4-related disease (IgG4-RD)

The 2 groups in the trial

  • ZB012Treatment being tested

    Obexelimab administered as an SC injection.

    Treatment: Obexelimab

  • PlaceboPlacebo, for comparison

    Placebo administered as an SC injection.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients With IgG4-Related Disease (INDIGO)
Publications
Record updated
4 February 2026